Cardiol Therapeutics Statistics
Total Valuation
CRDL has a market cap or net worth of $122.68 million. The enterprise value is $103.26 million.
Important Dates
The next estimated earnings date is Thursday, August 13, 2026, after market close.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CRDL has 115.27 million shares outstanding. The number of shares has increased by 24.11% in one year.
| Current Share Class | 115.27M |
| Shares Outstanding | 115.27M |
| Shares Change (YoY) | +24.11% |
| Shares Change (QoQ) | +11.28% |
| Owned by Insiders (%) | 2.96% |
| Owned by Institutions (%) | 11.07% |
| Float | 96.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.08 |
| P/TBV Ratio | 7.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.39 |
| Quick Ratio | 3.93 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -173.96% and return on invested capital (ROIC) is -105.79%.
| Return on Equity (ROE) | -173.96% |
| Return on Assets (ROA) | -78.25% |
| Return on Invested Capital (ROIC) | -105.79% |
| Return on Capital Employed (ROCE) | -146.60% |
| Weighted Average Cost of Capital (WACC) | 6.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.30% in the last 52 weeks. The beta is 0.48, so CRDL's price volatility has been lower than the market average.
| Beta (5Y) | 0.48 |
| 52-Week Price Change | -27.30% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 30.61 |
| Average Volume (20 Days) | 364,406 |
Short Selling Information
The latest short interest is 2.08 million, so 1.81% of the outstanding shares have been sold short.
| Short Interest | 2.08M |
| Short Previous Month | 1.92M |
| Short % of Shares Out | 1.81% |
| Short % of Float | 2.16% |
| Short Ratio (days to cover) | 5.80 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.50M |
| Pretax Income | -26.04M |
| Net Income | -26.04M |
| EBITDA | -25.48M |
| EBIT | -25.50M |
| Earnings Per Share (EPS) | -$0.28 |
Full Income StatementBalance Sheet
The company has $19.83 million in cash and $83,395 in debt, giving a net cash position of $19.74 million or $0.17 per share.
| Cash & Cash Equivalents | 19.83M |
| Total Debt | 83,395 |
| Net Cash | 19.74M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 17.34M |
| Book Value Per Share | 0.15 |
| Working Capital | 17.29M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$17.35 million and capital expenditures -$43,077, giving a free cash flow of -$17.10 million.
| Operating Cash Flow | -17.35M |
| Capital Expenditures | -43,077 |
| Depreciation & Amortization | 16,710 |
| Net Borrowing | -39,001 |
| Free Cash Flow | -17.10M |
| FCF Per Share | -$0.15 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |